This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
CJC-1295 NO DAC (5 mg Vial)
CJC-1295 NO DAC is a synthetic 29-amino-acid GHRH analogue (also known as Modified GRF 1–29 or Mod GRF) studied for stimulation of natural, pulsatile growth hormone secretion from the pituitary gland[1][2]. Unlike exogenous GH administration, CJC-1295 NO DAC preserves the body’s physiologic feedback loop, supporting enhanced GH and IGF-1 levels while maintaining natural hormonal rhythms[3][4]. Research suggests benefits may include improved body composition, enhanced recovery, better sleep quality, and support for lean muscle mass and metabolic function[5][6].
Quick Reference
What is CJC-1295 NO DAC?
Research overview based on the cited scientific literature.
• Goal: Stimulate pulsatile GH release and elevate IGF-1 levels to support body composition, recovery, and overall metabolic health[2][5].
• Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at 2–8 °C (35.6–46.4 °F); for extended storage, freeze at ≤−20 °C (≤−4 °F); minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1–2 weeks; avoid freeze–thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is CJC-1295 NO DAC studied?
CJC-1295 NO DAC (Modified GRF 1–29) is a truncated GHRH analog with four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that enhance stability against enzymatic degradation[1]. It binds to GHRH receptors on pituitary somatotrophs, stimulating the synthesis and pulsatile release of endogenous growth hormone[2][3]. Unlike exogenous GH administration, GHRH analogs preserve the physiologic feedback loop, resulting in more natural GH pulsatility without the risks associated with supraphysiological GH levels[7]. The short half-life (~30 minutes) produces discrete GH pulses that mimic the body’s natural secretion pattern[1][4].
What does the research report about CJC-1295 NO DAC?
Observations from preclinical and clinical literature on GHRH analogs.
• Stimulates pulsatile GH release and elevates IGF-1 levels with chronic administration[2][5][6].
• May support improvements in body composition, including increased lean mass and reduced fat mass[8][9].
• May enhance recovery, sleep quality, and overall energy levels[10].
• Generally well tolerated; occasional mild side effects may include injection-site reactions (redness, swelling), transient flushing, or headache[11].
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on CJC-1295 NO DAC?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.